John Hunter Peel Alexander, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Durham, NC 27701
Phone (919) 668-8955
Email address john.h.alexander@duke.edu

John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.

Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.

Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).

Education and Training

  • Fellow in Cardiology, Medicine, Duke University, 1996 - 2000
  • Medical Resident, Medicine, Children's Hospital Boston, 1993 - 1996
  • M.D., University of Pennsylvania, 1993

Publications

Carnicelli, Anthony P., Sana M. Al-Khatib, Denis Xavier, Frederik Dalgaard, Peter D. Merrill, Daniel M. Wojdyla, Basil S. Lewis, et al. “Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.” Heart 107, no. 9 (May 2021): 713–20. https://doi.org/10.1136/heartjnl-2020-317229.

PMID
32938772
Full Text

Lopes, Renato D., Pedro Gabriel Melo de Barros E Silva, Remo H. M. Furtado, Ariane Vieira Scarlatelli Macedo, Eduardo Ramacciotti, Lucas Petri Damini, Bruna Bronhara, et al. “Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial.” Am Heart J 238 (April 20, 2021): 1–11. https://doi.org/10.1016/j.ahj.2021.04.005.

PMID
33891907
Full Text

Gaudino, Mario, Antonino Di Franco, Deepak L. Bhatt, John H. Alexander, Antonio Abbate, Lorenzo Azzalini, Sigrid Sandner, et al. “The association between coronary graft patency and clinical status in patients with coronary artery disease.” Eur Heart J 42, no. 14 (April 7, 2021): 1433–41. https://doi.org/10.1093/eurheartj/ehab096.

PMID
33709098
Full Text

Hijazi, Ziad, John H. Alexander, Zhuokai Li, Daniel M. Wojdyla, Roxana Mehran, Christopher B. Granger, Alexander Parkhomenko, et al. “Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.” Circulation 143, no. 12 (March 23, 2021): 1215–23. https://doi.org/10.1161/CIRCULATIONAHA.120.051020.

PMID
33461308
Full Text

Al-Khatib, Sana M., Hillary Mulder, Daniel Wojdyla, Renato D. Lopes, Lars Wallentin, John H. Alexander, Ziad Hijazi, Shinya Goto, and Christopher B. Granger. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.” Circ Arrhythm Electrophysiol 14, no. 3 (March 2021): e009614. https://doi.org/10.1161/CIRCEP.120.009614.

PMID
33657831
Full Text

Carnicelli, Anthony P., Hwanhee Hong, Robert P. Giugliano, Stuart J. Connolly, John Eikelboom, Manesh R. Patel, Lars Wallentin, et al. “Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.” Am Heart J 233 (March 2021): 48–58. https://doi.org/10.1016/j.ahj.2020.12.002.

PMID
33296688
Full Text

Al-Khatib, Sana M., Hillary Mulder, Daniel Wojdyla, Renato D. Lopes, Lars Wallentin, John H. Alexander, Ziad Hijazi, Shinya Goto, and Christopher B. Granger. “Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy.” Circulation: Arrhythmia and Electrophysiology 14, no. 3 (March 2021). https://doi.org/10.1161/circep.120.009614.

Full Text

Pol, Tymon, Ziad Hijazi, Johan Lindbäck, John H. Alexander, M Cecilia Bahit, Raffaele De Caterina, J. W. Eikelboom, et al. “Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas.” Open Heart 8, no. 1 (March 2021). https://doi.org/10.1136/openhrt-2020-001471.

PMID
33741689
Full Text

Lopes, Renato D., Amit N. Vora, and John H. Alexander. “Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention-Reply.” Jama Cardiol 6, no. 2 (February 1, 2021): 241. https://doi.org/10.1001/jamacardio.2020.4759.

PMID
33026416
Full Text

Lopes, Renato D., Ariane V. S. Macedo, Pedro G. M. de Barros E Silva, Renata J. Moll-Bernardes, Tiago M. Dos Santos, Lilian Mazza, André Feldman, et al. “Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.” Jama 325, no. 3 (January 19, 2021): 254–64. https://doi.org/10.1001/jama.2020.25864.

PMID
33464336
Full Text

Pages